Stock 688192 DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Stock

Equities

688192

CNE1000055W8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-09 pm EDT 		5-day change 1st Jan Change
40.78 CNY -4.07% Intraday chart for Dizal (Jiangsu) Pharmaceutical Co., Ltd. -9.48% -14.78%
Apr. 29 Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 Dizal Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2023 91.29M 12.64M Sales 2024 * 401M 55.55M Capitalization 16.95B 2.35B
Net income 2023 -1.11B -153M Net income 2024 * -1.01B -140M EV / Sales 2023 214 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 42.2 x
P/E ratio 2023
-17.6 x
P/E ratio 2024 *
-16.7 x
Employees 424
Yield 2023 *
-
Yield 2024 *
-
Free-Float 18.48%
More Fundamentals * Assessed data

Chart Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Dizal Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer CI
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations CI
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine CI
Dizal Pharmaceutical Co., Ltd.(SHSE:688192) added to Shanghai Stock Exchange Health Care Sector Index CI
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH CI
Dizal Pharma to Invest 700 Million Yuan in New Dermatology Venture MT
Dizal Pharma Presents Positive Results of Lung Cancer Drug MT
Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients CI
Chinese Drug Regulator Puts Dizal Pharma's Lymphoma Drug in Priority Review MT
Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL CI
Dizal Pharmaceutical Co., Ltd.(XSSC:688192) added to S&P Global BMI Index CI
Dizal Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL CI
Dizal (Jiangsu) Pharmaceutical's Anti-Lymphoma Medication Research Results Published in European Oncology Journal MT
More news

Quotes and Performance

1 day-4.07%
1 week-9.48%
Current month-9.48%
1 month-3.50%
3 months+30.50%
6 months-9.98%
Current year-14.78%
More quotes

Highs and lows

1 week
40.30
Extreme 40.3
46.20
1 month
34.31
Extreme 34.31
47.44
Current year
24.82
Extreme 24.82
48.83
1 year
24.82
Extreme 24.82
54.58
3 years
19.02
Extreme 19.02
56.12
5 years
19.02
Extreme 19.02
56.12
10 years
19.02
Extreme 19.02
56.12
More quotes

Managers and Directors - Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Xiao Lin Zhang CEO
 Chief Executive Officer 60 17-10-26
Wei Wen Dong CHM
 Chairman 38 18-05-31
Hong Bin Lu DFI
 Director of Finance/CFO 46 20-06-30
Members of the board TitleAgeSince
Simon Lü BRD
 Director/Board Member 56 17-09-30
Xue Gong Wang BRD
 Director/Board Member 52 20-09-06
Guan Shan Zhu BRD
 Director/Board Member 60 20-09-07
More insiders

Quotes

Date Price Change Volume
24-05-10 40.78 -4.07% 2,833,072
24-05-09 42.51 -1.37% 2,725,683
24-05-08 43.1 -4.12% 3,110,860
24-05-07 44.95 -2.13% 1,869,510

End-of-day quote Shanghai S.E., May 09, 2024

More quotes

Company Profile

Dizal Jiangsu Pharmaceutical Co Ltd is a China-based company mainly engaged in the exploration, research, development and commercialization of innovative biomedicine. The Company focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The Company is still in the R&D stage.
Sector
Biotechnology & Medical Research
Calendar
2024-06-01 - American Society of Clinical Oncology Annual Meeting - Abstract No : 8513
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
40.78 CNY
Average target price
54 CNY
Spread / Average Target
+32.42%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. Stock Dizal (Jiangsu) Pharmaceutical Co., Ltd.
-14.78% 2.35B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 105B
ARGENX SE Stock argenx SE
+1.28% 22.25B
BIONTECH SE Stock BioNTech SE
-13.14% 22.09B
GENMAB A/S Stock Genmab A/S
-7.05% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 16.85B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 13.76B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.46B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 688192 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW